Saturday, June 7, 2025 – Clinical trials are carefully designed research studies conducted in humans to evaluate the safety, efficacy, and overall benefit of medical interventions such as drugs, biologics, or devices. They progress through phases 1 to 4, each…
Thursday, June 5, 2025 – Enforcement discretion means that a regulatory agency like the FDA (U.S. Food and Drug Administration) chooses not to enforce certain rules or regulations under specific circumstances, even if technically a violation has occurred. This is…
Thursday, June 5, 2025 – Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide’s role in modern obesity…
Wednesday, June 4, 2025 – Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA…
Wednesday, June 4, 2025 – Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs…
Wednesday, June 4, 2025 – by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that…
Tuesday, June 3, 2025 – This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor agonists (GLP-1s) for obesity treatment, highlighting their efficacy in weight reduction and other…
Monday, June 2, 2025 – PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo…
Sunday, June 1, 2025 – Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41, no. 3 (Spring 2025): 24–26. Laura A. Schmidt is a…
Saturday, May 31, 2025 – Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with…